Press enter or spacebar to select a desired language.
Press enter or spacebar to select a desired language.
Guidelines International Network (GIN)
Powered by EBSCO

Guidelines International Network

2471 - 2480 of 3876 results found

Nationale kliniske anbefalinger for behandling med melatonin ved søvnforstyrrelser hos børn og unge

MeSH Terms
Sleep (F02.830.855); Child (M01.060.406); Adolescent (M01.060.057)
Guideline Contact
Birgitte Holm Petersen ([email protected])
English Title Translation
National clinical recommendations for melatonin treatment of sleep disturbances in children and adolescents
Publication Scope
assessment
management
treatment
Countries of Application
Denmark
Guideline Publication Status
Published
Languages
Danish
Authors
SST (DK)
Publication Year
2022

Nationale kliniske anbefalinger om brug af lægemidler ved forebyggelse og behandling af covid-19

MeSH Terms
COVID-19 Drug Treatment (E02.319.231)
Guideline Contact
Birgitte Holm Petersen ([email protected])
English Title Translation
National clinical recommendations for use of medicines in the prevention and treatment of covid-19
Publication Scope
assessment
management
prevention
treatment
Countries of Application
Denmark
Guideline Publication Status
Published
Languages
Danish
Authors
SST (DK)
Publication Year
2023

Nationale kliniske retningslinje for brug af antibiotika ved tandlægebehandling

MeSH Terms
Drug Resistance, Bacterial (G06.099.225); Dentists (M01.526.485.330); Anti-Bacterial Agents (D27.505.954.122.085)
Guideline Contact
Birgitte Holm Petersen ([email protected])
English Title Translation
National clinical guideline for the use of antibiotics in dental treatment
Publication Scope
assessment
management
treatment
Countries of Application
Denmark
Guideline Publication Status
Published
Languages
Danish
Authors
SST (DK)
Publication Year
2019

Necesidades en cuidados paliativos de las enfermedades no oncológicas. Un estudio cualitativo desde la perspectiva de profesionales, pacientes y personas cuidadoras (Informe nº: Osteba E12/02)

MeSH Terms
Palliative Care (E02.760.666); Chronic Disease (C23.550.291.500); Needs Assessment (N05.300.537); Qualitative Research (H01.770.644.241.850)
English Title Translation
Palliative care requirements in the case of non-oncological diseases. A qualitative study from the perspective of professionals, patients and carers
Publication Scope
assessment
management
Countries of Application
Spain
Guideline Publication Status
Published
Languages
Spanish
Authors
OSTEBA (ES)
Publication Year
2012

Neoadjuvant and adjuvant systemic therapy for newly diagnosed stage II, III, or IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma

MeSH Terms

ovarian neoplasms, ovary tumour, ovary, fallopian tube, primary peritoneal, cancer, neoplasm, adenocarcinoma, carcinoma, malignant, tumour, metastases, drug therapy, antineoplastic agent, chemotherapy, adjuvant chemotherapy, consolidation chemotherapy, antineoplastic combined chemotherapy protocols, molecular targeted therapy, systemic, biologic, targeted, immunotherapy, hormone, maintenance, therapy, treatment, adriamycin, carboplatin, cisplatin, platinum, platamin, neoplatin, cismaplat, cis-diamminedichloroplatinum, cisdiamminedichloroplatinum, cyclophosphamide, doxorubicin, epirubicin, gemcitabine, irinotecan, isosfamide, paclitaxel, taxane, etoposide, platinum, MEK inhibitor, PD-325901, selumetinib, AZD6244, PD184352, CI-1040, PD035901, TAK-733, binimetinib, MEK162, ARRY-162, ARRY-438162, trametinib, GSK1120212, mekinist, cobimetinib, cotellic, XL518, GDC-0973, poly(ADP-ribose) polymerase inhibitors, olaparib, AZD2281, lynparza, AZD221, veliparib, ABT888, talazoparib, BMN673, nintedanib, iniparib, oregovomab, abagovomab, CA-125, MUC 16, pazopanib, niraparib, MK4827, rucaparib, PF-01367338, AG014699, rapamune, rapamycin, sirolimus, I2190A, AY 22989, cediranib, recentin, AZD2171, antibodies, monoclonal, humanized, bevacizumab, avastin, mTOR inhibitor, temsirolimus, CCI 779, torisel, everolimus, afinitor, certican, RAD001, SDZ-RAD, deforolimus, ridaforolimus, MK8669, AP23573, BRAF inhibitor, PLX8394, vemurafenib, RG7204, R05185426, PLX4032 or PLX-4032, zelboraf, dabrafenib, tafinlar, GSK2118436, tumour-infiltrating lymphocyte therapy, cytokines, IL-2, interferon, IFN-alpha, immune checkpoint inhibitor, thalidomide, sedoval, thalomid, revlimid, lenalidomide, CC5013, S-3APG, pomalidomide, pomalyst, imnovid, CC-4047, bacille calmette-guerin, tamoxifen, tomaxithen, zitazonium, soltamox, novaldex, nolvadex, ICI47699, ICI46474, fareston, fulvestrant, faslodex, ZM 182780, ICI182780, letrozole, femara, CGS-20267, anastrozole, arimidex, ICI D1033, ZD-1033, examestane, aromasin, FCE-24304, cystorelin, dirigestran, factrel, GnRH, gonadoliberin, luliberin, gonadotropin-releasing hormone, kryptocur, LFRH, luteinizing hormone-releasing hormone, angiogenesis inhibitor, aromatase inhibitor, topotecan, hycamtamine, NSC-609699, SKF104864A, oxaliplatin, eloxatin, docetaxol, taxotere, RP-56976, trabectedin, ecteinascidin, yondelis, ET-743, NSC 684766

Guideline Contact
Raymond Poon; [email protected]
Keywords
ovarian neoplasms, ovary tumour, fallopian tube, primary peritoneal, drug therapy, antineoplastic combined chemotherapy protocols
Date for Review
In Program in Evidence-Based Care (PEBC), Ontario Health (Cancer Care Ontario), we have an annual review process for each guideline after it is completed. Guidelines are reviewed every fall after they are older than 1 year.
Publication Date
2021-01-27
Date of Last Evidence Search
Oct-20
Methods Applied
Systematic review-based, Externally reviewed, Evidence quality assessment, GRADE approach
Publication Scope
Guidelines
treatment
Countries of Application
Canada
Guideline Publication Status
Published
Languages
English
Authors
PEBC (Program in evidenced-based care)
Publication Year
2021
My Saved Lists